Advertisement

The Placebo Effect in Overactive Bladder Syndrome

  • Svjetlana Lozo
  • Peter K. Sand
Chapter

Abstract

Initially seen as a nuisance variable, the placebo effect has been widely recognized as a distinct determinant of health in a number of different diseases and conditions. Some of the popular theories explaining the placebo effect are a “regression to the mean,” “expectancy theory,” “classical conditioning” theory, “context effect,” “meaning response,” and learned response theory. The effect of placebo in overactive bladder syndrome (OAB) has been examined from a number of different perspectives. It has been postulated that conservative treatment options, which include keeping a bladder diary and counseling about fluid intake and receiving education about the storage and voiding phases of the micturition cycle, have significantly influenced improvement in patients’ symptoms. Two large meta-analyses examined the placebo effect in OAB. Lee et al. showed that individual studies utilized two approaches to try to manage the placebo response: the first approach was to enroll more severely affected patients, and the second approach was to use a larger study size to decrease the placebo response. Magnera et al. found that placebo led to a statistically significant improvement in four out of five commonly reported OAB parameters. Neither study could determine which definitive factor played a significant role in their findings. The placebo effect plays a significant role in the treatment of OAB. This stems from the fact that treatment of OAB is complex and involves significant behavioral and physiological changes. While placebo effects have a greater impact on subjective versus objective outcome measures, they seem to significantly influence both in OAB.

Keywords

Overactive bladder Placebo Urinary urgency Urgency incontinence Nocturia 

References

  1. 1.
    Shapiro AK. Factors contributing to the placebo effect: their implications for psychotherapy. Am J Psychother. 1964;18(Suppl 1):73–88.CrossRefGoogle Scholar
  2. 2.
    Colagiuri B, Schenk LA, Kessler MD, Dorsey SG, Colloca L. The placebo effect: from concepts to genes. Neuroscience. 2015;307:171–90.CrossRefGoogle Scholar
  3. 3.
    Galton F. Regression towards mediocrity in hereditary stature. J Anthropol Inst G B Irel. 1886;15:246–63.Google Scholar
  4. 4.
    Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004;130(2):324–40.CrossRefGoogle Scholar
  5. 5.
    Lundh LG. Suggestion, suggestibility, and the placebo effect. Hypn Int Monogr. 2000;4:71–90.Google Scholar
  6. 6.
    Bootzin R. The role of expectancy in behavior change. In: White L, Tursky B, Schwartz GE, editors. Placebo: theory, research, and mechanisms. New York: Guilford Press; 1985. p. 196–210.Google Scholar
  7. 7.
    Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271(20):1609–14.CrossRefGoogle Scholar
  8. 8.
    Kirsch I, Lynn SJ, Vigorito M, Miller RR. The role of cognition in classical and operant conditioning. J Clin Psychol. 2004;60(4):369–92.CrossRefGoogle Scholar
  9. 9.
    Ader R, Cohen N. Behaviorally conditioned immunosuppression. Psychosom Med. 1975;37(4):333–40.CrossRefGoogle Scholar
  10. 10.
    Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet. 2001;357(9258):757–62.CrossRefGoogle Scholar
  11. 11.
    Moerman DE, Jonas WB. Toward a research agenda on placebo. Mind Body Med. 2000;16(1):33–46.Google Scholar
  12. 12.
    Thomas KB. General practice consultations: is there any point in being positive? Br Med J (Clin Res Ed). 1987;294(6581):1200–2.CrossRefGoogle Scholar
  13. 13.
    Colloca L, Miller FG. How placebo responses are formed: a learning perspective. Philos Trans R Soc Lond Ser B Biol Sci. 2011;366(1572):1859–69.CrossRefGoogle Scholar
  14. 14.
    Meissner K, Distel H, Mitzdorf U. Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials. BMC Med. 2007;5:3.CrossRefGoogle Scholar
  15. 15.
    Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P; International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28(4):287.CrossRefGoogle Scholar
  16. 16.
    Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. 2006;175(3 Pt 2):S5–10.CrossRefGoogle Scholar
  17. 17.
    Mangera A, Chapple CR, Kopp ZS, Plested M. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011;8(9):495–503.CrossRefGoogle Scholar
  18. 18.
    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al.; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63.CrossRefGoogle Scholar
  19. 19.
    Nicolson P, Kopp Z, Chapple CR, Kelleher C. It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008;13(Pt 2):343–59.CrossRefGoogle Scholar
  20. 20.
    Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, Hadley EC. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.CrossRefGoogle Scholar
  21. 21.
    Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;4:CD003781.Google Scholar
  22. 22.
    Herschorn S, Chapple CR, Snijder R, Siddiqui E, Cardozo L. Could reduced fluid intake cause the placebo effect seen in overactive bladder clinical trials? Analysis of a large solifenacin integrated database. Urology. 2017;106:55–9.CrossRefGoogle Scholar
  23. 23.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al.; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.Google Scholar
  24. 24.
    Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102(1):62–6.CrossRefGoogle Scholar
  25. 25.
    Zinner NR, Ammann LP, Haas GP, Janning SW, He W, Bukofzer S. Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects. Neurourol Urodyn. 2013;32(4):308–13.CrossRefGoogle Scholar
  26. 26.
    Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009;9:55.CrossRefGoogle Scholar
  27. 27.
    Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81(6):801–10.CrossRefGoogle Scholar
  28. 28.
    Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280(23):1995–2000.CrossRefGoogle Scholar
  29. 29.
    Cardozo L, Lisec M, Millard R, van Vierssen TO, Kuzmin I, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172(5 Pt 1):1919–24.CrossRefGoogle Scholar
  30. 30.
    Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93(1):71–7.CrossRefGoogle Scholar
  31. 31.
    Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93(3):303–10.CrossRefGoogle Scholar
  32. 32.
    Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–12.CrossRefGoogle Scholar
  33. 33.
    Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, Sanders SW; Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168(2):580–6.Google Scholar
  34. 34.
    Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW; Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237–42.CrossRefGoogle Scholar
  35. 35.
    Dmochowski R, Sand P, Zinner NR, Staskin DR. Trospium chloride 60 mg once daily (QD) for overactive bladder syndrome: results of a placebo-controlled interventional study. Urology. 2008;71(3):449–54.CrossRefGoogle Scholar
  36. 36.
    Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Brünjes R, Frank M, Wieners F. The elderly patient with urge incontinence or urge-stress incontinence–efficacy and cardiac safety of propiverine. Aktuelle Urol. 2003;34(2):102–8. (Article in German).CrossRefGoogle Scholar
  37. 37.
    Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):283–9.CrossRefGoogle Scholar
  38. 38.
    Halaska M, Dorschner W, Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourol Urodyn. 1994;13:428–30.Google Scholar
  39. 39.
    Herschorn S, Heessakkers J, Castro-Diaz D, Brodsky M. Tolterodine extended release (TER) improves objective and subjective outcomes after 1 week of treatment in patients with overactive bladder (OAB) (abstract). Int Urogynecol J. 1994;18(Suppl 1):S78.Google Scholar
  40. 40.
    Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92(7):741–7.CrossRefGoogle Scholar
  41. 41.
    Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol. 2001;98(1):97–102.CrossRefGoogle Scholar
  42. 42.
    Jünemann KP, Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: a double-blind, placebo-controlled, multicentre clinical trial. Neurourol Urodyn. 2000;19(4):488–90.Google Scholar
  43. 43.
    Jünemann KP, Hessdörfer E, Unamba-Oparah I, Berse M, Brünjes R, Madersbacher H, Gramatté T. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006;77(4):334–9.CrossRefGoogle Scholar
  44. 44.
    Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release a randomized, placebo-controlled trial. Urology. 2004;64(2):269–74. discussion 274–5CrossRefGoogle Scholar
  45. 45.
    Lee KS, Choo MS, Paick JS, Lee JG, Seo JT, Lee JZ, et al. Propiverine hydrochloride reduced frequency and perception of urgency in treatment of overactive bladder: a 12 week prospective, randomized, double-blind, placebo controlled study (Abstract 279). International Continence Society; 29 Nov–1 Dec 2006; Christchurch, New Zealand.Google Scholar
  46. 46.
    Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84(6):646–51.CrossRefGoogle Scholar
  47. 47.
    Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001;49(6):700–5.CrossRefGoogle Scholar
  48. 48.
    Malone-Lee J, Whately-Smith C. A study of the significance of identifying detrusor instability in the treatment of overactive bladder symptoms (abstract 228). International Continence Society 2002; Heidelberg, Germany; 28–30 Aug 2002.Google Scholar
  49. 49.
    Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999;161(5):1551–5.CrossRefGoogle Scholar
  50. 50.
    Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol. 2007;178(6):2488–94.CrossRefGoogle Scholar
  51. 51.
    Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z; 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731–6.CrossRefGoogle Scholar
  52. 52.
    Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability. Br J Urol. 1998;81(1):42–8.CrossRefGoogle Scholar
  53. 53.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007;100(4):840–5.CrossRefGoogle Scholar
  54. 54.
    Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(11):1551–7.CrossRefGoogle Scholar
  55. 55.
    Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275–80.CrossRefGoogle Scholar
  56. 56.
    Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007;178(3 Pt 1):978–83.CrossRefGoogle Scholar
  57. 57.
    Thüroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991;145(4):813–6; discussion 816–7.CrossRefGoogle Scholar
  58. 58.
    Uchida T, Tempel D, Ridge S, Grimes I, Smith N. US PII study results: efficacy and safety of YM905, a bladder-selective treatment for OAB (abstract). Int Urogynecol J. 2002;13:S12.Google Scholar
  59. 59.
    Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414–21.CrossRefGoogle Scholar
  60. 60.
    Wang A, Chih S, Chen M. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology. 2006;68(5):999–1004.CrossRefGoogle Scholar
  61. 61.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, et al.; Japanese Solifenacin Study Group. Randomized, double-blind, placebo-and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100(3):579–87.CrossRefGoogle Scholar
  62. 62.
    Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 Pt 1):2311–5. quiz 2435CrossRefGoogle Scholar
  63. 63.
    Chapple C. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract 142). International Continence Society 2004; Paris, France; 27 Aug 2004.Google Scholar
  64. 64.
    Homma Y, Koyama N. Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence. Neurourol Urodyn. 2006;25(3):228–35.CrossRefGoogle Scholar
  65. 65.
    Jonas U, Höfner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol. 1997;15(2):144–51.CrossRefGoogle Scholar
  66. 66.
    Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, et al.; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008;102(9):1120–7.Google Scholar
  67. 67.
    Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23(4):248–52.CrossRefGoogle Scholar
  68. 68.
    Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 1990;66(5):479–85.CrossRefGoogle Scholar
  69. 69.
    Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol. 1984;11(1–2):37–42.PubMedGoogle Scholar
  70. 70.
    Kuhtz-Buschbeck JP, van der Horst C, Pott C, Wolff S, Nabavi A, Jansen O, Jünemann KP. Cortical representation of the urge to void: a functional magnetic resonance imaging study. J Urol. 2005;174(4 Pt 1):1477–81.CrossRefGoogle Scholar
  71. 71.
    Matsumoto S, Ishikawa A, Matsumoto S, Homma Y. Brain response provoked by different bladder volumes: a near infrared spectroscopy study. Neurourol Urodyn. 2011;30(4):529–35.CrossRefGoogle Scholar
  72. 72.
    Staskin D, Dmochowski R, Serels S, Andoh M, Smith M. Report from a randomized, placebo-controlled study showing significant improvement in urgency and patient-reported outcomes in over-active bladder patients treated with solifenacin. Int Urogynecol J. 2007;18:S73–4.CrossRefGoogle Scholar
  73. 73.
    Eickhoff JC. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials. Stat Med. 2008;27(9):1387–402.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Svjetlana Lozo
    • 1
  • Peter K. Sand
    • 2
  1. 1.Division of Urogynecology, Department of Obstetrics & GynecologyNorthShore University HealthSystem, University of Chicago Pritzker School of MedicineSkokieUSA
  2. 2.Division of Urogynecology, Department of Obstetrics & GynecologyNorthShore University HealthSystem, University of Chicago Pritzker School of MedicineWinnetkaUSA

Personalised recommendations